Clinical trial

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

NCT04362072

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Lorlatinib Normalized identity: lorlatinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-09-29

PhasePHASE4

Conditions

Carcinomaverified · MONDO: carcinoma

Non-Small-Cell Lungunresolved

Interventions

LorlatinibDRUG · verified · RxNorm: lorlatinib

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

SzczecinPoland4 BarcelonaSpain3 ManchesterUnited Kingdom2 LondonUnited Kingdom1 ValenciaSpain1 SevilleSpain1 OrangeCalifornia, United States1 MálagaSpain1 LublinPoland1 A CoruñaSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04362072 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.